ARDX (Ardelyx) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ARDX Ardelyx Inc ARDX
74 GF Score
Price $5.14
GF Value $10.30
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

ARDX
74GF Score
Ardelyx Inc ARDX
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ardelyx (ARDX) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of $5.14 is trading 50.1% below its estimated GF Value™ of $10.30. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for ARDX:

  • Dividends Received:
  • GF Value™: $10.30 vs. price of $5.14 (50.1% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ardelyx Business Description

Other Exchanges ARDX:Mexico41X:Germany
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
74GF Score

Get the complete analysis for ARDX

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.14
Price
$10.30
GF Value